Standard Contracts
JOINT COMMERCIALIZATION AGREEMENT by and between GENMAB A/S and SEAGEN INC. Dated as of October 19, 2020Joint Commercialization Agreement • March 29th, 2021 • Genmab a/S • Pharmaceutical preparations • New York
THIS JOINT COMMERCIALIZATION AGREEMENT (this “Agreement”) is made as of October 19, 2020 (the “Effective Date”), by and between GENMAB A/S, a Danish corporation (“Genmab”), and SEAGEN INC. (f/k/a SEATTLE GENETICS, INC.), a Delaware corporation (“SGI”). Genmab and SGI are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
BetweenJoint Commercialization Agreement • March 8th, 2000 • Dendreon Corp • California
First Amendment to the Joint Commercialization Agreement 2 “4.3 Taxes. 4.3.1 Tax Partnership. Each Party understands, acknowledges and agrees that to the extent the Parties are sharing Net Profits and Net Losses pursuant to Section 4.1.1 with respect...Joint Commercialization Agreement • July 29th, 2021 • Seagen Inc. • Biological products, (no disgnostic substances) • California
JOINT COMMERCIALIZATION AGREEMENTJoint Commercialization Agreement • March 10th, 2023 • Cingulate Inc. • Pharmaceutical preparations • Delaware
This Joint Commercialization Agreement (this “Agreement”) is made on March 7th 2023 (the “Effective Date”) by and between Indegene, Inc., a Delaware corporation having its place of business at Suite 104, 150 College Road W, Princeton, NJ 08540 (hereinafter referred to as “Indegene”) and Cingulate Therapeutics LLC, a Delaware limited liability company having its corporate office at 1901 W 47th Place, 3rd Floor, Kansas City, KS 66205 (hereinafter referred to as “Cingulate”). Indegene and Cingulate may be referred to individually as a “Party” and together referred to as the “Parties”. Capitalized terms in the Agreement not otherwise defined shall have the meaning set forth in Section 1 below.
The contract for the joint commercialization of HLC-001 in regenerative medicine productsJoint Commercialization Agreement • March 28th, 2023
This material is an English translation of the press release to be issued on March 28, 2023 in Japanese, and the Japanese release is given priority regarding content and interpretation.
JOINT COMMERCIALIZATION AGREEMENTJoint Commercialization Agreement • July 16th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • California
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
